Canterbury DHB


Rarely-used Opioids

Buprenorphine (Temgesic™) injection is inferior to morphine and is NOT recommended. Low dose transdermal buprenorphine (NorspanTM) has recently been licensed in New Zealand but is not funded. It is unlikely that it will be used commonly in Palliative Care but its efficacy and appropriateness are yet to be established.

Hydromorphone is not available in New Zealand.


Note: The risk of pethidine toxicity is increased with high doses and/or long term use and SHOULD NOT be used in chronic cancer-related pain.

About this Canterbury DHB document (4431):

Document Owner:

Kate Grundy (see Who's Who)

Issue Date:

February 2013

Next Review:

August 2014


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 4431